Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadoterate in patients with renal dysfunction
NCT02382380Phase 4Terminated
- Sponsor
- Loyola University Chicago
- Start
- Nov 2014
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial of gadoterate meglumine in head neoplasm, Neck neoplasm, brain neoplasm and 5 more, sponsored by Loyola University Chicago. Primary endpoint: Change in Glomerular Filtration Rate at 72 hours. Started Nov 2014; status: terminated.
02
Drugs
gadoterate meglumine
03
Conditions
head neoplasmNeck neoplasmbrain neoplasmliver neoplasmpancreatic neoplasm
Beyond the preview
Go deeper on NCT02382380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382380.